Bioventus Q2 revenue misses estimates on surgical solutions decline

Bioventus

05/08/2026 12:41

Overview
US medical device maker's Q2 revenue rose 4% but missed analyst expectations
Adjusted EPS for Q2 rose to $0.22 from $0.21 a year earlier
Company initiates review of strategic alternatives after receiving acquisition interest

Outlook
Bioventus reaffirms 2026 net sales guidance of $600 mln to $610 mln
Company maintains 2026 adjusted EPS guidance of $0.75 to $0.79
Bioventus initiates review of strategic alternatives, including potential sale

Result Drivers
PAIN TREATMENTS GROWTH - Double-digit growth in Pain Treatments, driven by strong volume in Durolane hyaluronic acid therapy and favorable customer mix
SURGICAL SOLUTIONS DECLINE - Revenue fell due to a challenging prior-year comparison and timing shift of Ultrasonics capital placements and international orders
RESTORATIVE THERAPIES DECREASE - Revenue declined due to change in customer mix for EXOGEN Bone Stimulation System and tough prior-year comparison

Company press release: ID:nGNX9dFHxV

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Miss
$153.20 mln
$155.64 mln (5 Analysts)
Q2 Adjusted EBITDA
 
$35.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Bioventus Inc. is $15.00, about 11.8% above its August 4 closing price of $13.42
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
Aug 5 - Orthofix Medical Q2 sales slightly beat estimates
Aug 5 - Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand
Aug 3 - Integer Holdings Q2 sales fall 2.6%; KKR to buy company for $5.7 billion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)